Pacira BioSciences Inc
For the period ended Sep 30, 2024. Filed Nov 6, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 6, 2024
PCRX$36.46+0.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
The exhibits listed below are filed or furnished as part of this report.
| Exhibit Number | Description |
| 10.1 | Employment Agreement, dated April 19, 2012, between the Registrant and Lauren Riker.(1)*** |
| 10.2 | Amendment No. 1 to Employment Agreement, dated March 13, 2013, between the Registrant and Lauren Riker.(2)*** |
| 10.3 | Amendment No. 2 to Employment Agreement, dated June 30, 2015, between the Registrant and Lauren Riker.* *** |
| 10.4 | Amendment No. 3 to Employment Agreement, dated August 16, 2024, between the Registrant and Lauren Riker.* *** |
| 10.5 | Non-Healthcare Professional Consulting Agreement, effective October 1, 2024, between the Registrant and Charles. A. Reinhart, III* *** |
| 10.6 | Amended and Restated 2014 Inducement Plan.* *** |
| 10.7 | Form of Nonstatutory Stock Option Agreement under the Amended and Restated 2014 Inducement Plan.* *** |
| 10.8 | Form of Restricted Stock Unit Award Agreement under the Amended and Restated 2014 Inducement Plan.* *** |
| 31.1 | Certification of Chief Executive Officer pursuant to Rule 13a-14(a) and 15d-14(a), as amended.* |
| 31.2 | Certification of Chief Financial Officer pursuant to Rule 13a-14(a) and 15d-14(a), as amended.* |
| 32.1 | Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.** |
| 101 | The following materials from the Quarterly Report on Form 10-Q of Pacira BioSciences, Inc. for the quarter ended September 30, 2024, formatted in iXBRL (Inline eXtensible Business Reporting Language): (i) the Condensed Consolidated Balance Sheets; (ii) the Condensed Consolidated Statements of Operations; (iii) the Condensed Consolidated Statements of Comprehensive (Loss) Income; (iv) the Condensed Consolidated Statements of Stockholders’ Equity; (v) the Condensed Consolidated Statements of Cash Flows; and (vi) the Condensed Notes to Consolidated Financial Statements.* |
| 104 | Cover Page Interactive Data File (Formatted as Inline XBRL and contained in Exhibit 101). |
| * | Filed herewith. |
| ** | Furnished herewith. |
| *** | Denotes management contract or compensatory plan or arrangement. |
| (1) | Incorporated by reference to the exhibits to the registrant's Quarterly Report on Form 10-Q, filed on May 9, 2012. |
| (2) | Incorporated by reference to the exhibits to the registrant’s Current Report on Form 8-K, filed on March 18, 2013. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.